Terutroban (S18886), a specific thromboxane A2 receptor antagonist, which improves endothelial function and has an antiatherosclerotic effect. The compound is under development by Servier for the potential treatment of cardiovascular diseases and coronary artery disease. In addition, it participated in phase III clinical trials PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack), but this study was stopped, and the result was not achieved.

Decloxizine (UCB-1402; NSC289116) is a histamine 1 receptor antagonist. Decloxizine is a broncholyticum.

Decitropine is an anticholinergic and antiulcer agent, developed by Koninklije Pharma FAB NV in the 1960s.

Moxiraprine (also known as CM-30366) is aminopyridazine derivative with antidepressant activity. In preclinical studies Moxiraprine induced stereotyped behaviour and antagonized haloperidol-induced catalepsy in rats, after parenteral and oral administration. In 6-hydroxy dopamine (6-OHDA)-lesioned mice, Moxiraprine induced contralateral rotations and, when injected before 6-OHDA, protected mice against its neurotoxicity. Moxiraprine also provoked contralateral rotations when injected directly into the mouse right striatum. After parenteral injection, Moxiraprine slightly increased motility in mice, at least at low doses. The stereotypies and rotations (after intrastriatal injection) induced by Moxiraprine were antagonized by haloperidol, alpha-methyl-p-tyrosine and reserpine. The effects of Moxiraprine were compared to those of direct and indirect dopamine-like drugs. Bromocriptine induced a behavioural profile, which in most aspects, was qualitatively and quantitatively similar to that of Moxiraprine. Apomorphine was found slightly more potent than Moxiraprine, but in contrast to the latter, apomorphine-induced stereotypies were insensitive to alpha-methyl-p-tyrosine or reserpine. (+)-Amphetamine and nomifensine were less potent than Moxiraprine, and unlike Moxiraprine, induced ipsilateral rotations in 6-OHDA-lesioned mice.

Darotropium is a muscarinic acetylcholine antagonist, developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). Darotropium in combination with salmeterol was investigated in phase 2 clinical trial in COPD patients. The addition of darotropium to salmeterol in partially reversible COPD patients resulted in greater bronchodilation than salmeterol or tiotropium alone and was well tolerated. In a clinical trial of darotropium as monotherapy, all doses of the drug were well tolerated and demonstrated bronchodilatory activity. However, the rapid onset of bronchodilation was not sustained over 24 h, and GSK has discontinued the development of darotropium in favor of GSK573719, which has more favorable pharmacokinetics.

Serlopitant, Originally developed by Merck, is a once-daily oral NK1 receptor antagonist being developed for the treatment of pruritus, or itch, associated with various conditions such as prurigo nodularis, psoriasis and chronic pruritus of unknown origin. It is highly selective for the human NK1 receptor and in both animal and human testing it has been well tolerated. In 2012, Merck licensed serlopitant to Menlo to develop it in indications other than nausea and vomiting. Development of serlopitant for the treatment of overactive bladder, alcohol dependence and pruritus was discontinued at phase II, by Merck & Co. and Japan. Menlo has completed three positive Phase 2 clinical trials with serlopitant showing a statistically significant reduction in pruritus compared to placebo. Serlopitant has been evaluated in over 1,600 patients and has been shown to be well-tolerated, including in patients who have received treatment for up to one year. Serlopitant is an investigational drug that is not currently approved for use in any indication in any country.

Roxibolone, an androstane derivative, possesses the anti-glucocorticoid activity and devoid of any affinity for the androgenic prostate and muscle receptors. This anabolic drug has never been marketed.

Pentabamate was developed as an anxiolytic agent and was studied as a minor tranquilizer by Bayer. Information about the current use of this drug is not available.

Cicrotoic acid is a biochemical drug that acts on bile flow and liquid composition of human bile.